PX-1: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 23: | Line 23: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:PX-1.svg|PX-1 | |||
</gallery> | |||
Latest revision as of 00:00, 25 February 2025
PX-1 is a synthetic cannabinoid which is found in many synthetic cannabis products. It is also known as 5F-APP-PICA and SRF-30. PX-1 is a potent agonist for the cannabinoid receptors, with a Ki of 2.6 nM at CB1 and 1.2 nM at CB2.
History[edit]
PX-1 was first identified in Japan in 2012. It was found in a synthetic cannabis product called "Funky Monkey". Since then, it has been identified in many other synthetic cannabis products around the world.
Pharmacology[edit]
PX-1 is a potent agonist for the cannabinoid receptors. It has a Ki of 2.6 nM at CB1 and 1.2 nM at CB2. This makes it more potent than THC, the main active ingredient in cannabis. The effects of PX-1 are similar to those of THC, but can be more intense and longer lasting.
Legal Status[edit]
The legal status of PX-1 varies by country. In the United States, it is a Schedule I controlled substance. In the United Kingdom, it is a Class B drug. In Canada, it is a Schedule II drug. In Australia, it is a Schedule 9 drug.
Health Risks[edit]
The health risks of PX-1 are not well understood. However, it is known that synthetic cannabinoids can cause a range of adverse effects, including seizures, psychosis, and death. It is also known that PX-1 can be more potent than THC, which suggests that it may carry a higher risk of adverse effects.
